Jingsong Zhang Selected Research

Jingsong Zhang Research Topics

Disease

37	Neoplasms (Cancer) 10/2022 - 09/2004
23	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 07/2013
9	Urinary Bladder Neoplasms (Bladder Cancer) 10/2022 - 01/2014
7	Carcinoma (Carcinomatosis) 03/2022 - 01/2014
2	Circulating Neoplastic Cells 03/2022 - 12/2019
2	Fatigue 01/2022 - 11/2018
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 01/2021
2	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2019
2	Cataract (Cataracts) 08/2021 - 01/2020
2	Disease Progression 03/2021 - 11/2017
2	Inflammation (Inflammations) 01/2020 - 02/2018
2	Infections 11/2017 - 01/2010
2	Hypoxia (Hypoxemia) 05/2015 - 06/2014
2	Rhabdomyosarcoma 06/2005 - 09/2004
1	Anemia 01/2022
1	Exanthema (Rash) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Kidney Neoplasms (Kidney Cancer) 01/2022
1	Asthenia 01/2022
1	Neuroendocrine Carcinoma 10/2021
1	Adenocarcinoma 10/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2021
1	Residual Neoplasm 01/2021
1	Stomach Ulcer (Gastric Ulcer) 09/2020
1	Hepatocellular Carcinoma (Hepatoma) 01/2020
1	Non-Muscle Invasive Bladder Neoplasms 01/2020
1	Blindness (Hysterical Blindness) 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2019
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2019

Drug/Important Bio-Agent (IBA)

8	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 05/2014
6	Biomarkers (Surrogate Marker)IBA 03/2022 - 11/2017
6	abirateroneIBA 01/2022 - 11/2017
5	Pharmaceutical PreparationsIBA 01/2020 - 01/2014
4	rucaparibIBA 01/2022 - 01/2020
4	AndrogensIBA 01/2021 - 11/2017
4	Androgen Receptors (Androgen Receptor)IBA 01/2019 - 11/2018
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
3	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 01/2012
3	Polysaccharides (Glycans)IBA 11/2019 - 01/2007
3	AntioxidantsIBA 11/2019 - 01/2011
3	Small Interfering RNA (siRNA)IBA 05/2015 - 01/2014
2	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2020
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2022 - 05/2014
2	Abiraterone AcetateIBA 01/2022 - 01/2021
2	Interleukin-2 (IL2)IBA 01/2022 - 01/2018
2	Biological ProductsIBA 01/2020 - 02/2018
2	enfortumab vedotinIBA 01/2020 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2018
2	durvalumabIBA 01/2020 - 09/2017
2	Phosphotransferases (Kinase)IBA 01/2019 - 12/2018
2	Messenger RNA (mRNA)IBA 12/2018 - 01/2014
2	Complement System Proteins (Complement)IBA 02/2018 - 01/2007
2	Testosterone (Sustanon)FDA Link 12/2017 - 11/2017
2	DNA (Deoxyribonucleic Acid)IBA 05/2015 - 06/2014
2	Phosphatidylinositols (Phosphatidylinositol)IBA 04/2007 - 09/2004
1	Gemcitabine FDA Link 10/2022
1	Cisplatin (Platino)FDA LinkGeneric 10/2022
1	Cell-Free Nucleic AcidsIBA 03/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	pembrolizumabIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	NivolumabIBA 01/2021
1	Ethanol (Ethyl Alcohol)IBA 09/2020
1	pyranoprofen (pranoprofen)IBA 01/2020
1	bromfenac FDA Link 01/2020
1	AlbuminsIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	GlucocorticoidsIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	PlatinumIBA 01/2020
1	Serum AlbuminIBA 01/2020
1	Tobramycin (Nebcin)FDA LinkGeneric 01/2020
1	Dinoprostone (PGE2)FDA Link 01/2020
1	PrebioticsIBA 01/2020
1	Long Noncoding RNAIBA 01/2020
1	Radium-223IBA 12/2019
1	FlavonoidsIBA 11/2019
1	antrodin CIBA 03/2019
1	NADP (NADPH)IBA 03/2019
1	Checkpoint Kinase 1IBA 01/2019
1	serum P-component (CIt)IBA 01/2019
1	enzalutamideIBA 01/2019
1	apalutamideIBA 01/2019
1	Protein Kinases (Protein Kinase)IBA 01/2019

Therapy/Procedure

24	Therapeutics 01/2022 - 07/2013
12	Castration 01/2022 - 07/2013
6	Neoadjuvant Therapy 10/2022 - 11/2016
6	Drug Therapy (Chemotherapy) 10/2022 - 01/2018
5	Cystectomy 10/2021 - 01/2014
3	Immunotherapy 03/2022 - 01/2021
2	Lasers (Laser) 08/2021 - 01/2020
1	Nephrectomy 01/2022
1	Ligation 01/2022
1	Radiotherapy 01/2021
1	Oncolytic Virotherapy 01/2021
1	Brachytherapy 01/2021
1	Aftercare (After-Treatment) 01/2020
1	Phacoemulsification 01/2020
1	Perioperative Period 01/2020